NasdaqCM:CPRXBiotechs
Catalyst Pharmaceuticals Record 2025 Results Highlight Rare Disease Growth Story
Catalyst Pharmaceuticals (NasdaqCM:CPRX) reported record full year and Q4 2025 results, highlighting organic growth across its portfolio.
The company noted continued market uptake of its lead rare disease treatments, including AGAMREE and FIRDAPSE.
Management discussed how recent alliances and product momentum position Catalyst within the rare disease treatment space.
Catalyst Pharmaceuticals focuses on therapies for rare neurological and neuromuscular conditions, an area where treatment...